Clene Inc. (CLNNW) Aandelenanalyse

Bedrijfsoverzicht

Clene Inc. is a clinical-stage pharmaceutical entity dedicated to the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics, with its lead drug candidate CNM-Au8 currently undergoing various clinical trials including a completed Phase 2 platform. The company operates within the pharmaceutical sector, specifically focusing on therapeutic advancements utilizing nanotechnology, though specific industry classifications and broader sector labels are not provided in available data. Clene Inc. maintains a workforce of 75 employees and possesses a cash balance of $7.92 million, while its market capitalization, annual revenue, and price-to-book ratio are currently listed as N/A or negative/zero in the available records. The absence of a defined market cap and the presence of significant negative net income indicate that the company is in a pre-revenue profitability stage where valuation is driven by pipeline potential rather than current earnings multiples. The revenue figure of $214,000 suggests a very small operational scale relative to established pharmaceutical peers, highlighting that the firm's primary value proposition lies in its research and development activities rather than existing commercial sales volume.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $214,000, yet recorded a net income of $-30,496,000, revealing a substantial gap that indicates heavy investment in research, development, and operational overhead costs that far exceed current sales generation. The EBITDA stands at $-22,703,000, further confirming that operating expenses, including cost of goods sold and general administrative costs, are significantly draining the company's cash reserves before interest and tax adjustments. Free cash flow is reported at $-13,295,375, which signifies a lack of financial flexibility to fund operations or capital expenditures from internal cash flows without relying on external financing or cash reserves. The gross margin is calculated at 82.2%, suggesting that the cost of revenue is low relative to sales, likely due to the nature of early-stage development or low unit production costs, whereas the operating margin is a staggering -37653.3% and the profit margin is 0.0%, both indicating that the company is not yet generating profitable operations on a per-unit basis. On the balance sheet, the company holds $7.92 million in cash against total debt of $21.31 million, creating a negative net cash position, while the debt-to-equity ratio is not available and the price-to-book ratio is listed as -0.00. The current ratio is 1.53, indicating that the company possesses sufficient liquid assets to cover its short-term liabilities, providing a baseline of liquidity despite the negative cash flow situation. Return on equity is not available due to the lack of positive equity metrics in the dataset, while return on assets is -56.2%, revealing that management is currently utilizing the asset base to generate losses rather than returns.

Waarderingsbeoordeling

The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that standard earnings-based valuation models are not applicable given the company's negative earnings history and lack of positive net income in the trailing twelve months. The price-to-book ratio is recorded as -0.00, suggesting that the market does not currently assign a positive premium over book value, likely due to the significant accumulated losses and negative equity position reflected in the financial statements. The price-to-sales ratio and EV/EBITDA are also listed as N/A, indicating that alternative valuation metrics typically used for high-growth or pre-profitability companies are either unavailable or not calculated by the data provider. The 52-week high and low are both recorded as $0.00, which implies that the stock is either suspended, delisted, or trading in a range where price data is not actively reported, making it impossible to calculate a percentage deviation from a historical trading range. The beta value is 0.79, indicating that the stock's theoretical price volatility is lower than the broader market, though this metric is often less reliable for companies with limited trading activity or those that do not trade at a standard market price.

Growth & Income

Revenue growth year-over-year is reported at -82.8%, while earnings growth year-over-year is N/A, indicating a significant contraction in top-line revenue without the context of prior year earnings to establish a growth trajectory. The decline in revenue suggests that the company is not yet achieving the commercial scale necessary to support its operational costs, and the lack of earnings growth data reinforces the company's status as an early-stage entity focused on development rather than commercial expansion. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning that any available cash or potential future earnings are retained within the company to fund research and development efforts rather than being distributed to shareholders. The overall growth and income profile is characterized by negative revenue expansion and the absence of income generation, reflecting a strategic focus on long-term therapeutic discovery rather than short-term financial returns or shareholder distributions.